comparemela.com

Latest Breaking News On - Biomea fusion - Page 8 : comparemela.com

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J P Morgan Healthcare Conference

09.01.2024 - Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., . Seite 1

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesThe clinical study, COVALENT-112, has initiated.

Cramer s Lightning Round: Move on from Tidewater

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.